+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06923527

Phase II Trial of Elacestrant as Circulating Tumor DNA-Guided Adjuvant Therapy for Adults with Hormone Receptor Positive HER2 Negative Breast Cancer at Risk of Late Recurrence

Led by Yale University · Updated on 2026-09-21

50

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating elacestrant in a single-arm, phase II trial for patients with estrogen receptor-positive ER breast cancer who test positive for circulating tumor DNA ctDNA. The study focuses on those with anatomic stage IIB or III breast cancer diagnosed at least five years ago and who have completed adjuvant endocrine therapy and are currently off such therapy. This trial aims to assess elacestrants impact on ctDNA clearance and invasive disease-free survival in this population. Participants who test positive for ctDNA during screening will receive oral elacestrant at an FDA-approved dose of 345 mg daily for up to 12 months. Treatment continues until disease progression or unacceptable toxicity occurs. During treatment, ctDNA testing and CT scans will be performed every three months. If ctDNA remains positive after 12 months, participants may continue treatment for an additional 12 months or choose to resume standard endocrine therapy or surveillance. After treatment, a one-year follow-up period will include ctDNA testing every six months. Throughout the study, participants will undergo regular imaging, laboratory tests, and assessments of treatment safety, adherence, anxiety, and fear of recurrence. Patient-reported outcomes and lifestyle factors such as diet and physical activity will also be collected. The primary outcomes include monitoring ctDNA clearance and invasive disease-free survival over an 18-month period. The total study duration includes screening, treatment, and follow-up phases lasting up to approximately three years.

CONDITIONS

Brief Title

Circulating Tumor DNA

Research Team

L

Laura Kane

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here